Skip to main content

Truist Financial Remains a Buy on Adicet Bio (ACET)

Tipranks - Tipranks - Thu Oct 9, 2025

Truist Financial analyst Asthika Goonewardene maintained a Buy rating on Adicet Bio today. The company’s shares closed yesterday at $0.85.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Goonewardene covers the Healthcare sector, focusing on stocks such as Summit Therapeutics, Arcus Biosciences, and Genmab. According to TipRanks, Goonewardene has an average return of -8.0% and a 38.43% success rate on recommended stocks.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Adicet Bio with a $5.80 average price target, which is a 579.87% upside from current levels. In a report released yesterday, Guggenheim also reiterated a Buy rating on the stock with a $8.00 price target.

See today’s best-performing stocks on TipRanks >>

Based on Adicet Bio’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $31.22 million. In comparison, last year the company had a GAAP net loss of $29.9 million

Read More on ACET:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).